Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Discontinuation of two CRYSTALIZE evidence trials | 1 Dec 2023 |
| Total Voting Rights | 1 Dec 2023 |
| Block listing Interim Review | 1 Dec 2023 |
| Director/PDMR Shareholding | 23 Nov 2023 |
| Truqap approved in US for HR+ breast cancer | 17 Nov 2023 |
| Update on PACIFIC-2 Phase III trial for Imfinzi | 14 Nov 2023 |
| 9M and Q3 2023 results | 9 Nov 2023 |
| Agreement with Eccogene for clinical stage GLP-1RA | 9 Nov 2023 |
| Imfinzi combination improves PFS in liver cancer | 9 Nov 2023 |
| Director Declaration | 9 Nov 2023 |
| AstraZeneca cell & gene therapy deal w/ Cellectis | 1 Nov 2023 |
| Total Voting Rights | 1 Nov 2023 |